Molecular Docking, Antioxidant, Anticancer and Antileishmanial Effects of Newly Synthesized Quinoline Derivatives
-
Published:2020-09-14
Issue:13
Volume:20
Page:1516-1529
-
ISSN:1871-5206
-
Container-title:Anti-Cancer Agents in Medicinal Chemistry
-
language:en
-
Short-container-title:ACAMC
Author:
Malghani Zoonish1, Khan Arif-Ullah1, Faheem Muhammad1, Danish Muhammad Z.2, Nadeem Humaira1, Ansari Sameen F.1, Maqbool Madeeha1
Affiliation:
1. Riphah Institute of Pharmaceutical Sciences, Riphah International University, Islamabad, Pakistan 2. University College of Pharmacy, University of the Punjab, Lahore, Pakistan
Abstract
Background:
Due to the pressing need and adverse effects associated with the available anti-cancer
agents, an attempt was made to develop the new anti-cancer agents with better activity and lesser adverse
effects.
Objective:
Synthetic approaches based on chemical modification of quinoline derivatives have been undertaken
with the aim of improving anti-cancer agents’ safety profile.
Methods:
In the present study, quinoline derivatives 6-hydroxy-2-(4-methoxyphenyl) quinoline-4-carboxylic
acid (M1) and 2-(4-chlorophenyl)-6-hydroxyquinoline-4-carboxylic acid (M3) were synthesized by the reaction
of aldehyde and pyruvic acid. The complete reaction was indicated by thin-layer chromatography. Newly synthesized
M1and M3were tested for in silico and in vitro studies.
Results:
M1 and M3 were docked against selected targets. Both the test compounds showed good affinity against
all targets except the p300\CBP-associated factor target as there was no H-bond formed by M1. IC50 values of
M1 and M3 against 1, 1-diphenyl-picrylhydrazyl free radical scavenging activity were 562 and 136.56ng/mL,
respectively. In brine shrimp lethality assay, M1 and M3 showed IC50 value of 81.98 and 139.2ng/mL, respectively.
IC50 values recorded for M1 and M3 in tumor inhibition activity were 129 and 219μg/mL, respectively.
M1 and M3 exhibited concentration-dependent anti-cancer effects against human cell lines of hepatocellular
carcinoma (HepG2) and colon cancer (HCT-116). Against HepG2 cells, M1 and M3 exhibited IC50 of 88.6 and
43.62μg/mL, respectively. M1 and M3 utilized against HCT-116 cell lines possessed IC50 values of 62.5 and
15.3μg/mL. M1 and M3 also showed an anti-leishmanial effect with IC50 values of 336.64 and 530.142μg/mL,
respectively.
Conclusion:
From the results of pharmacological studies, we conclude that the newly synthesized compound
showed enhanced anti-oxidant, anti-cancer and anti-leishmanial profile with good yield.
Publisher
Bentham Science Publishers Ltd.
Subject
Cancer Research,Pharmacology,Molecular Medicine
Reference31 articles.
1. Varadhachary, G.R.; Tamm, E.P.; Abbruzzese, J.L.; Xiong, H.Q.; Crane, C.H.; Wang,H.; Lee, J.E.; Pisters, P.W.; Evans, D.B.; Wolff, R.A. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann. Surg. Oncol. 2006,13(8),1035-1046. http://dx.doi.org/10.1245/ASO.2006.08.011 PMID: 16865597 2. Rami, P.D.; Ball, J.J.; Crowley. The IASLC Lung Cancer Staging Project. Proposals for revision of the T descriptors in the forthcom-ing (seventh) ed ition of the TNM Classification of Malignant tu-mour, J. Thorac. Oncol. 2007,2,593-602. http://dx.doi.org/10.1097/JTO.0b013e31807a2f81 PMID: 17607114 3. McBee.; W. Jr; Gardiner, A.S.; Edwards, R.P.; Lesnock,J.; Bhar-gava, R. MicroRNA analysis in Human Papillomavirus (HPV)-associated cervical neoplasia and cancer, J. Carcinog. Mutagen. 2011,1,1-23 4. Naga Deepthi,C.; Pavan, K.A.; Rameshbabu, I.U. Role of tumor suppressor protein p53 in apoptosis and cancer therapy, J. Cancer Sci. Ther. 2011,17,2-6 5. Nair.; A. Amplified hypoxia induced tumor-cell death, J. Carcinog. Mutagen. 2010,1,1-4. http://dx.doi.org/10.4172/2157-2518.1000109
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|